Sign inJoin waitlistJoin the waitlist

Sara Hurvitz

Senior Vice President and Director, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · · · ·

History

Division of Hematology and Oncology · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of California-Los Angeles
2002–2005
Internal Medicine
University of California-Los Angeles
1999–2002
Keck Sch of Med of the Univ of Southern Calif
1995–1999
Biology), BA (Psychology), University of California, Irvine

Research

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
New England Journal of Medicine · 2018 · 1,704 citations
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
New England Journal of Medicine · 2020 · 1,630 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations

Hope Rugo
45 papers
Dennis Slamon
34 papers
Aditya Bardia
32 papers
AB
Adam Brufsky
21 papers
EH
Erika Hamilton
20 papers
JO
Joyce O'Shaughnessy
18 papers
Sara Tolaney
16 papers
DY
Denise Yardley
15 papers
Lisa Carey
13 papers
Kevin Kalinsky
11 papers
Gabriel Hortobagyi
9 papers
IK
Ian Krop
9 papers

Clinical trials

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Principal investigator · Terminated · Phase 1
Jonsson Comprehensive Cancer Center
2017–2022
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Principal investigator · Completed · Phase 1, Phase 2
Jonsson Comprehensive Cancer Center
2013–2019
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Principal investigator · Completed
Jonsson Comprehensive Cancer Center
2010
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
Principal investigator · Completed · Phase 2
Translational Oncology Research International
2009